Semaglutide Works Broadly. Can GLP1R Genes Predict Response?

Semaglutide can produce large average benefits, but averages do not tell a patient whether the drug will work well for them. A 2025 study offers an intriguing possible clue: a variant in the GLP1R gene, combined with biological sex, tracked with different short-term weight-loss responses. It does not yet support genetic testing to choose treatment. The study was small, observational, and has not been replicated.

That caution matters because semaglutide's population-level record is substantial. A 2026 systematic review and meta-analysis of 35 randomized controlled trials involving 36,847 participants found a mean weight reduction of 12.4 kg (95% CI, −13.0 to −11.8) and an HbA1c reduction of 1.52 percentage points (95% CI, −1.60 to −1.44). The participants had a mean BMI of 34.8 and a mean age of 54.2. The drug's benefits reach well beyond the scale, but "12 body systems" should describe the scope of outcomes studied, not imply that semaglutide has solved human biology.

A broad evidence base, with unequal certainty

The 2026 multisystem meta-analysis used GRADE methodology and reported favorable semaglutide results across metabolic, cardiovascular, hepatic, renal, musculoskeletal, neurological, and quality-of-life domains. The most decision-relevant findings remain weight, glucose, and cardiovascular events. Major adverse cardiovascular events fell with a relative risk of 0.84 (95% CI, 0.77 to 0.92), a 16% relative reduction. Relative risk is not the same as an individual's absolute risk reduction: the personal payoff depends on baseline cardiovascular risk.

Cardiovascular evidence also extends beyond diabetes care. An analysis from the SELECT trial reported cardiovascular mortality benefit in adults with overweight or obesity who did not have type 2 diabetes. That population matters because it shows that semaglutide's clinical value is not confined to lowering glucose in diabetes.

The same meta-analysis reported renal protection with a hazard ratio of 0.76 (95% CI, 0.68 to 0.85), and a hepatic resolution endpoint with a relative risk of 1.84 (95% CI, 1.49 to 2.27). These are encouraging results, though the hepatic estimate is relative; without the underlying absolute event rates, it cannot tell a reader how many additional people achieved resolution. A separate 2025 randomized-trial meta-analysis of adults with overweight or obesity without diabetes also examined semaglutide's lipid effects, providing semaglutide-specific support for that metabolic domain.

Some of the wider claims deserve more restraint. The multisystem review reported an 87-meter increase in walking distance, a body-composition ratio of 87:13 fat to lean loss, and a 3.8-point SF-36 quality-of-life improvement. Its abstract does not report the number or size of trials behind each of those results, nor the certainty rating for each domain. They may be useful signals, but they do not carry the same evidentiary weight as the large-trial cardiovascular, glycemic, and weight-loss outcomes.

Why one patient loses far more than another

The landmark STEP 1 randomized trial established once-weekly semaglutide 2.4 mg as an effective obesity treatment in adults with overweight or obesity. Yet clinical response varies. Some people lose substantial weight, while others lose little or stop treatment because they cannot tolerate it. The available evidence does not provide a clean, comparable responder-rate breakdown for every setting, so no single percentage can summarize "nonresponse."

A prospective observational study of 112 patients with grade 3 obesity, all with BMI of at least 40 kg/m², asked whether GLP1R rs6923761 might explain some of that variation. Over four months of semaglutide treatment, AA homozygotes lost an average of 1.64% of body weight per month (SD 0.78), compared with 1.04% per month (SD 0.79) among people carrying at least one G allele; the difference was statistically significant (p=0.03). In multivariable analysis, both genotype and biological sex predicted response.

The study's most dramatic comparison came from its sex-by-genotype analysis. AA women lost 1.89% per month (SD 0.75), while G-allele men lost 0.70% per month (SD 0.70; p=0.0009). The authors classified 21 of 37 G-allele men, or 56%, as nonresponders. The publication's abstract does not define that threshold, so this figure cannot be compared directly with conventional trial thresholds such as 5% or 10% weight loss.

These results make biological sense as a hypothesis. Rs6923761 is a nonsynonymous GLP1R coding variant, so it could conceivably affect receptor behavior. But plausibility is not proof. The AA subgroup included only about nine people, which makes the subgroup interaction vulnerable to a false-positive result, especially without a reported correction for multiple comparisons. The study had no placebo group, lasted four months, and enrolled only people with severe obesity. No replication study, large pharmacogenomic cohort, genome-wide analysis, or relevant functional assay appears to confirm that this variant changes semaglutide response.

A GLP1R test cannot currently tell you whether semaglutide will work. It can tell you that a preliminary study found an association worth testing again.

Benefits do not erase tolerability or safety questions

Semaglutide's practical limitation is often gastrointestinal tolerance. A 2025 systematic review with trial sequential analysis in patients at increased cardiovascular risk found that adverse effects, including gastrointestinal symptoms, contribute materially to discontinuation. A treatment cannot deliver its trial benefit if a person cannot stay on it. Adverse-effect rates in lower-risk populations may differ, but nausea and vomiting deserve a real pre-treatment conversation rather than a footnote.

Eye safety also needs careful attention. A 2025 systematic review and meta-analysis of ocular adverse events raised a safety signal with semaglutide. Separately, a multinational population-based study associated semaglutide use with nonarteritic anterior ischemic optic neuropathy, or NAION, a potentially vision-threatening optic-nerve condition. Association does not prove semaglutide caused NAION; observational studies can retain confounding by diabetes, vascular risk, healthcare use, and other factors. Still, two independent lines of evidence justify individualized discussion, particularly for people with pre-existing optic-nerve disease or substantial vascular risk.

Lean mass is another unfinished issue for people who care about strength, function, or athletic performance. A 2025 network meta-analysis of 22 randomized trials and 2,258 participants found that GLP-1 receptor agonists reduced total weight by 3.55 kg, fat mass by 2.95 kg, and lean mass by 0.86 kg versus comparators. Lean loss accounted for about one-quarter of total weight loss in that analysis. It pooled GLP-1 drugs and dual agonists, so it does not settle the semaglutide-specific question. It does make one point plain: body weight alone is a poor scoreboard for a performance-focused patient.

Where semaglutide fits

Semaglutide has also begun to reach populations left out of its earliest landmark trials. In a 26-week double-blind trial of 72 adults with type 1 diabetes, obesity, and automated insulin delivery, 36% of participants assigned semaglutide achieved a composite glucose-and-weight endpoint, compared with 0% on placebo; the between-group difference was 36 percentage points (95% CI, 20.6 to 52.2; p<0.001). The trial is useful preliminary evidence, not a basis for broad conclusions about every person with type 1 diabetes.

Medication also belongs beside, not above, diet and activity. A 2024 meta-analysis of 10 randomized trials with 623 adults found that fasting-based and continuous calorie restriction both produced roughly 5.5 to 6.5 kg of weight loss at six months. The small short-term advantage for fasting was not clinically significant. The dietary-intervention evidence does not answer whether a particular patient should use semaglutide, but it does reject the lazy idea that medication is the only route to meaningful metabolic change.

For people with obesity or type 2 diabetes who meet clinical criteria, semaglutide has unusually well-supported benefits for weight, glycemic control, and cardiovascular events. Its kidney and liver findings add to the case in appropriate populations. The GLP1R rs6923761 result belongs in the research column, not the ordering-a-genetic-test column. If response disappoints, genotype is only one unproven possibility among dose, adherence, tolerance, baseline biology, and ordinary biological variation. Monitor symptoms, body composition when it matters, and vision changes with a clinician. The evidence supports a powerful drug; it does not support pretending we can yet predict every responder.